Even though AMPs are under investigation as novel therapeutics to defeat microbial infections, only a few studies have been reported to date on their antibacterial activity in the lungs of animal models of P. aeruginosa pneumonia31, 32. Remarkably, as learned from literature, when locally applied via intra-nasal or intra-tracheal route in murine models of acute lung infection, they are generally administered after a short time interval (5–15 min) from bacterial infection33, 34. Furthermore, to the best of our knowledge, no studies have been accomplished by the effect(s) of AMPs on the airway epithelial gene expression after P. aeruginosa-induced respiratory infection.